The management of RA may be affected by the promising candidates matrix metallopeptidase 9 (MMP-9), Bruton’s tyrosine kinase (BTK), IL-1 receptor-associated kinase 4 (IRAK4) [30], and p38 mitogen-activated protein kinases (p38 MAPK) [31]. This evidence concerns the gene BTK and rheumatoid arthritis.